首页> 外国专利> Biofilm developed on the basis of chitosan and healing the hydroalcoholic extract of croton cajucara Benth solubilized in nanoemulsão

Biofilm developed on the basis of chitosan and healing the hydroalcoholic extract of croton cajucara Benth solubilized in nanoemulsão

机译:在壳聚糖的基础上开发了生物膜,并修复了溶于纳米乳油中的巴豆Cajucara Benth的水醇提取物

摘要

The present invention consists in preparing a formulation for topical use in healing wounds.Developed the basis of biofilm of chitosan combined with nanoemulsion carrier of hydroalcoholic extract obtained from the bark of the stem of croton cajucara Benth (EHA - CC).The main goal of the treatment consists in the quick closure of the lesion, so as to obtain a scar functional and aesthetically satisfactory.Justified by the importance of reducing microbial contamination.Among the methods of treatment of wounds, the patch is used to protect, to absorb exudates and drain the wound, improving the conditions of the wound bed.Assisting in complete healing.In this sense, the biopolymer chitosan (quit) to provide biocompatibility, biodegradability, being non-toxic, possess antimicrobial activities and healing.As well as having the ability to form films resistant and elastic, represents an excellent matrix for the incorporation of drugs for various therapeutic uses.In this invention, EHA - CC extract solution (5 mg to 30 mg) in a system nanoemulsionados (snedds) was biocompatible with the biofilm (quit).From the composition quit / EHA - CC (1: 1) was the formulation quit - CC - snedds (biofilm chitosan containing the extract of EHA - CC incorporated into nanoemulsão type snedds - self - nanoemulsion drug deliveRy system). This set was employed in an experimental in vivo model with the purpose to investigate its potential healing in surgical wounds.The evolution of the healing process in treated animals was evaluated by histopathological studies, which observed the healing efficiency.Induction of neovascularization with satisfactory and formation of collagen fibers, in comparison with the biofilm quit (free of plant).In the present invention claims - if the topical use of biotechnology can quit - DC snedds in surgical wounds, sores, infected wounds, chronic ulcers, diabetic wounds.Burned, among other possibilities.In severe cases, recomenta if topical treatment of biofilm quit - CC - snedds associated with oral administration of nanoemulsão CC - snedds, who in turn.After the evaluation experiments in vivo inflammation and pain, has anti-inflammatory efficacy and anti pain.
机译:本发明在于制备用于伤口愈合的局部用制剂。开发了壳聚糖生物膜与从巴豆树汁(BHA)茎的树皮(EHA-CC)获得的水醇提取物的纳米乳液载体相结合的基础。治疗包括快速闭合病变,从而获得疤痕功能性和美学上令人满意的效果。减少微生物污染的重要性证明了这一点。在伤口的治疗方法中,该贴剂用于保护,吸收渗出液和渗出物。排干伤口,改善伤口床的状况。帮助完全愈合。从这个意义上讲,生物聚合物壳聚糖(退出)提供了生物相容性,可生物降解性,无毒,具有抗菌活性和愈合能力,并且具有形成具有抵抗力和弹性的薄膜,代表了用于各种治疗用途的药物掺入的优良基质。在本发明中,EHA-CC ext纳米乳状液(snedds)中的ract溶液(5 mg至30 mg)与生物膜(退出)具有生物相容性。从组成退出 / EHA-CC(1:1:1)组成退出-CC-snedds(生物膜壳聚糖)包含EHA-CC提取物,并掺入纳米乳液型snedds-自我纳米乳液药物交付系统)。该组被用于实验性体内模型中,目的是研究其在手术伤口中的潜在愈合能力。通过组织病理学研究评估了被治疗动物的愈合过程,观察了其愈合效率。与生物膜相比(没有植物),胶原纤维的数量减少了。在本发明中,如果可以局部使用生物技术,则在手术伤口,疮,感染的伤口,慢性溃疡,糖尿病伤口中使用直流电放电。除其他可能性外,在严重的情况下,如果局部使用生物膜的局部治疗-与口服纳米乳CC-snedds相关的患者再次服用,则经过评估后,在体内炎症和疼痛实验后,具有抗炎功效和抗疼痛。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号